Abivax
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7-11 Boulevard Haussmann, Paris, Ile-de-...Phone Number
+33 153830963Website
www.abivax.comRevenue
<$5 MillionStock Symbol
ABVXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Abivax
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax was founded in 2013 and based in Paris, France.Explore more
Abivax Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Abivax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Abivax had a recent Job posting/layoffs
Earning: See what the market has to say on Abivax recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Abivax has new funding data
Product Launch: Get notified when Abivax launches new products
Check if Abivax has recently received funding, and reach out quickly before it becomes old news!
Abivax, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Abivax
Check out if Abivax is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Abivax as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Abivax is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Abivax is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Abivax.
Abivax financials insights
Gather financial insights about Abivax, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Debt
$436K
2020
Debt
$17.6M
2022
Other Financing Round
$49M
Abivax Tech Stack
A closer look at the technologies used by Abivax
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Person-Based
Events, Podcast
Project
, according to a mid-level source in data & analytics, has completed initiatives related to dashboards and data visualization within the last twelve months.
Business Intelligence, Database, Analytics & Insights, Data Management, Data Science, Design & Graphics, Mapping & GIS
Project
Business Intelligence, Analytics & Insights, Data Science
Abivax News & Media
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of their value in a single session. NEW YORK, June 2, 2026 /PRNewswire/ -- Abivax (NASDAQ:...Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisAbivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative ColitisAbivax Announces Results of its May 11, 2026 Annual General Meeting
Abivax Announces Results of its May 11, 2026 Annual General Meeting
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Abivax
Sign Up For FreeTo access detailed company insights
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax was founded in 2013 and based in Paris, France.... Read More
